Table 4. Comparison of trials in patients with primary mediastinal nonseminomatous GST including conventional cisplatin-based regimen and high-dose chemotherapy.
|
Conventional dosea |
HD-VIP |
|||
|---|---|---|---|---|
| Variable | No. of pts | % | No. of pts | % |
| Patients | 253 | 28 | ||
| CR/PRm- (assessable) | 157 (244) | 45 | 17 (28) | 61 |
| Status | ||||
| NED | 114 | 45 | 17 | 61 |
| AwD | 11 | 4 | 1 | 4 |
| Dead | 121 | 48 | 10 | 36 |
| Lost to follow-up | 9 | 4 | – | – |
| Median 5-year PFS rate (%) | 42 | 56 | ||
| Median 5-year OS rate (%) | 46 | 64 | ||
| Median PFS (months) | 15 | Not reached | ||
| Median OS (months) | 40 | Not reached | ||
HD=high dose; CR=complete remission; PRm-=marker normalized partial remission; NED=no evidence of disease; AwD=alive with disease; PFS=progression-free survival; OS=overall survival; pts=patients.
a
Data about patients receiving standard cisplatin chemotherapy are derived from the database of the International Extragonadal Germ Cell Tumour Study Group (in part described in Bokemeyer et al, 2002, Hartmann et al, 2002).